Velodyne Lidar Demonstrates How Advanced Lidar Technology Can Improve Pedestrian Safety
18.3.2021 13:48:00 EET | Business Wire | Press release
While overall driving was down 13 percent in miles driven last year due to the COVID-19 pandemic, motor vehicle deaths were up 8 percent in the United States, reported the National Safety Council. Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today showed how with lidar technology, Pedestrian Automated Emergency Braking (PAEB) systems can be significantly improved, with the potential to save thousands of lives annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005164/en/
Velodyne released a new video that showcases how its affordable lidar-based PAEB solution delivers superior performance in all conditions, a decisive advantage over radar+camera-based systems. This is especially critical at night with the National Highway Traffic Safety Administration (NHTSA) reporting 80 percent of pedestrian fatalities occur during dark lighting conditions.
The Velodyne video presents striking test results where a highly-rated PAEB system using radar+camera-based technology failed in all six nighttime scenarios while the Velodyne PAEB solution avoided a crash in every situation. These results support independent testing by NHTSA and the American Automobile Association (AAA) to confirm whether PAEB systems which use radar+camera-based technology adequately protect pedestrians in dark conditions.
The Velodyne PAEB solution combines proprietary software, called Vella, with Velodyne’s lidar sensors. The sensors can be easily embedded in a variety of places around a vehicle, including behind the windshield. Vella software interprets lidar data to avoid and mitigate crashes with moving and static objects. Through predictive collision monitoring, Vella compares a vehicle’s trajectory with other road users and objects to identify and avoid imminent crash scenarios.
Velodyne is sharing the company’s PAEB test methodology and findings with NHTSA and other auto safety leaders. NHTSA has a pending proposal to update its New Car Assessment Program (NCAP), adding advanced driver assistance system (ADAS) capabilities, including PAEB, to the NCAP. Velodyne is very supportive of NHTSA’s NCAP plan to keep pace with evolving safety technologies and providing much-needed information to consumers, and looks forward to NHTSA leadership completing the review of this measure and moving ahead with its request for comment.
“Our PAEB testing initiative clearly demonstrates the imperative for regulatory agencies and testing organizations to include nighttime conditions in their PAEB assessment protocols,” said Anand Gopalan, CEO, Velodyne Lidar. “Everyone, particularly automakers and drivers will expect that ADAS, such as PAEB, perform effectively in a wide variety of lighting situations, particularly at night when the most pedestrian fatalities occur. We believe Velodyne’s lidar data and Vella processing software have shown to be effective and ready for implementation, with the potential to save the lives of thousands of pedestrians annually.”
Velodyne PAEB Testing Methodology
The Velodyne PAEB tests were conducted at nighttime, without streetlights, at less than 1 lux ambient lighting in an independent testing facility. The two vehicles in the test were driving at 30 mph on a straight track. The test vehicles each had their low beam headlights on during the trials. Stationary child and adult pedestrian dummy targets were used, compatible with testing protocols prescribed by Insurance Institute for Highway Safety (IIHS) and Euro NCAP.
Six scenarios were evaluated with both vehicles tested in each scenario five times or until the vehicle collided with the target three times, to minimize damage to the targets and vehicles. The scenarios in which vehicles were evaluated were crossing adult at 50 percent overlap (at the center of the test vehicle’s width); crossing adult at 25 percent overlap; crossing child at 50 percent overlap; crossing child at 25 percent, adult at 75 percent, 10 feet behind child; crossing adult at driver-side corner and fallen adult at 50 percent overlap.
The vehicle with Velodyne’s lidar-based PAEB system, equipped with one Velarray lidar sensor, successfully stopped in time to avoid a crash five out of five times for every scenario tested. The vehicle equipped with a PAEB system using radar+camera-based technology failed in every scenario tested.
Additional details on the Velodyne PAEB testing can be found in a white paper, called “Improving Pedestrian Automatic Emergency Braking (PAEB) in Dark, Nighttime Conditions.”
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include changes in laws, regulations or judicial interpretations to which Velodyne or its customers are subject; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; uncertainties related to Velodyne's estimates of the size of the markets for its products; uncertainties regarding government regulation and adoption of lidar for pedestrian safety, traffic congestion and smart city applications; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005164/en/
Contact information
Investor Relations
Andrew Hamer
Chief Financial Officer
InvestorRelations@velodyne.com
Media
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release
Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
